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Deﬁ ning new standards of care for men with prostate cancer
Improving the outcomes of medical or surgical 
castration for men with prostate cancer has been an 
elusive goal since the approach was ﬁ rst reported in 
the 1940s.1 However, this situation changed at the 
annual American Society of Clinical Oncology meeting in 
2014, when results reported from the ChemoHormonal 
Therapy Versus Androgen Ablation Randomized Trial for 
Extensive Disease (CHAARTED) showed that addition of 
six cycles of docetaxel to standard of care (testosterone 
lowering hormone therapy) prolonged the survival of 
men with metastatic disease at the time of diagnosis 
relative to treatment with hormones alone.2,3 The result 
contrasted with a trial of similar design, GETUG-AFU 15, 
that did not show a survival beneﬁ t.4
In The Lancet, Nicholas James and colleagues5 report on 
the Systemic Therapy in Advancing or Metastatic Prostate 
Cancer: Evaluation of Drug Eﬃ  cacy (STAMPEDE) study, a 
multinational trial of unparalleled scope and size designed 
to establish new standards of care for prostate cancer 
patients starting ﬁ rst-line hormone therapy. The report 
includes 2962 men with high-risk localised, node-only 
disease, and metastatic disease that was newly diagnosed 
or that relapsed after local therapy, who were randomised 
to one of four treatment groups: standard of care (SOC) 
alone, standard of care plus zoledronic acid (SOC + ZA), 
standard of care plus docetaxel (SOC + Doc), or standard of 
care plus zoledronic acid plus docetaxel (SOC + ZA + Doc).
Overall, relative to SOC alone, SOC + Doc reduced 
mortality by 22% (hazard ratio 0·78 [95% CI 0·66–0·93]), 
prolonged median overall survival by 10 months 
(81 months vs 71 months), and increased absolute 5-year 
survival by 8% (63% vs 55%). For the subset of patients 
with metastatic disease, the relative reduction in mortality 
was 24% (hazard ratio 0·76 [95% CI 0·62–0·92]), 
median survival increased by 15 months (60 months 
vs 45 months), and absolute 5-year survival increased 
by 11% (50% vs 39%). Favourable eﬀ ects on failure-free 
survival—deﬁ ned as time from randomisation to evidence 
of at least one of the following: biochemical failure; 
local, nodal, or metastatic progression; or death from 
prostate cancer—were also reported. No survival beneﬁ t, 
prolongation of failure-free survival, or reduction in the 
frequency of skeletal-related events was seen for adding 
zoledronic acid to either SOC alone or SOC + Doc. However, 
the addition of docetaxel did delay the time to the ﬁ rst 
skeletal-related event. Safety and tolerance were as 
anticipated for docetaxel and, although the frequency of 
grade 3 or higher adverse events was increased in the ﬁ rst 
6 months, the overall frequencies at 1 year were similar for 
the docetaxel and non-docetaxel treatment groups.
James and colleagues’ results5 provide further 
unequivocal level 1 evidence of a meaningful clinical 
beneﬁ t for early docetaxel relative to the potential risks 
and harms, leading the study authors to conclude that the 
“standard of care should be updated to include docetaxel 
chemotherapy in suitable patients with metastatic 
disease”, similar to the group shown to beneﬁ t in 
CHAARTED, and that it “may be considered for men with 
high-risk non-metastatic” disease. Adding zoledronic acid 
to standard of care was not recommended.5
Based on the results of STAMPEDE and CHAARTED, 
should all men with newly diagnosed or recurrent 
metastatic disease receive chemotherapy? No. Even 
though over 100 sites participated in STAMPEDE and 
accrual was not restricted to academic high volume 
centres, the patients enrolled were not representative 
of a general prostate cancer population in that 97% 
had no cardiovascular history, 99% no cerebrovascular 
history, 100% no history of congestive heart failure, and 
over 90% no history of diabetes. Few had performance 
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status 1 or greater. In a Canadian study,6 use of docetaxel 
in patients with metastatic castration-resistant prostate 
cancer by the same physicians at the same institution, 
at the same dose and schedule, oﬀ -protocol resulted 
in higher morbidity and inferior outcomes relative to 
patients treated on-protocol strictly on the basis of 
demographics. The non-castrate metastatic disease 
state includes patients with one or two lesions, 20 or 
more lesions, bone marrow entirely replaced by tumour, 
and those with or without symptoms. Tolerance and 
safety are unlikely to be the same in the two settings. 
The non-castrate metastatic state also includes 
patients metastatic at diagnosis and those who develop 
metastases after failing local therapy for whom median 
survival times are inherently longer,7 and, although there 
was no evidence of heterogeneity across subgroups, 
patients older than 70 years did not appear to beneﬁ t.5
Hidden factors might have aﬀ ected survival outcomes in 
favour of the groups treated with chemotherapy relative 
to those not treated with chemotherapy. Reported are 
the speciﬁ c therapies received and how long after a failure 
event was documented. Most failures were biochemical, 
and about 80% of patients in each group received a new 
treatment within 6 months. Most treatments were not 
life prolonging. During the course of STAMPEDE,5 four 
additional therapies proven to prolong life in metastatic 
castration-resistant prostate cancer became available, 
which were also given at a similar time and frequency to 
the four treatment groups after the failure event. Not 
surprisingly, a higher percentage of patients in the SOC 
alone and SOC + ZA groups received docetaxel and a lower 
percentage abiraterone, enzalutamide, or cabazitaxel 
relative to the SOC + Doc and SOC + Doc + ZA groups.
A concern is that 40% of patients in the non-
docetaxel containing groups had not received 
docetaxel or any other life-prolonging therapy. These 
imbalances could have aﬀ ected the survival outcome 
in favour of early chemotherapy. Notable here is that 
the relative percentage of patients receiving a newly 
approved life-prolonging therapy and docetaxel in the 
SOC +  Doc group relative to the standard of care groups 
in CHAARTED which showed a survival beneﬁ t was 25% 
and 50% greater than GETUG-AFU 15, a trial that largely 
accrued before these therapies were available and 
showed no survival beneﬁ t.7 Showing the post-failure 
survival of the four groups, although not deﬁ nitive, 
could shed some light. An additional question that 
has not been formally addressed by either STAMPEDE 
or CHAARTED, and which remains open, is whether 
chemotherapy given early versus chemotherapy given 
later at the time of failure or progression would have 
produced similar overall survival times.8
For patients with non-metastatic disease, the hazard 
ratio for the reduction in mortality was similar to that 
observed in metastatic patients, but the results are not 
deﬁ nitive due to the short follow-up and insuﬃ  cient 
number of events. An important amendment to the 
STAMPEDE trial in 2011 was to require radiation therapy 
to the primary tumour, previously shown to improve 
survival relative to standard of care hormone therapy 
or radiation therapy alone.9,10 For these patients, failure 
rates and overall prostate cancer-speciﬁ c death rates 
are lower than for men with metastatic disease and 
the net beneﬁ t of early chemotherapy is less certain. 
For those not at risk of dying of prostate cancer, or who 
have tumours that can be successfully treated with 
standard of care hormones and local therapy alone, or 
who have tumours that are insensitive to docetaxel, any 
chemotherapy is overtreatment.
Additionally, in The Lancet Oncology, Claire Vale 
and colleagues11 have reported a meta-analysis that 
considers ongoing trials that might aﬀ ect outcomes, 
based solely on completed studies. The conclusions 
for metastatic (M1) disease were based on the results 
of CHAARTED,3 GETUG-AFU 15,4 and STAMPEDE5 
representing 2992 (93%) of the 3206 patients enrolled 
in the relevant trials. The combined analysis showed an 
absolute 9% (95% CI 5–14) improvement in survival at 
4 years, and makes it essential that the role of docetaxel 
in combination with hormones be discussed. However, 
for an individual patient careful consideration must be 
given to comorbidities that might compromise tolerance 
and the ability to give chemotherapy safely. For patients 
with locally advanced (M0) disease, failure-free survival 
was consistently prolonged with docetaxel (hazard ratio 
0·70 [95% CI 0·61–0·81]) but an eﬀ ect on survival has 
not been ﬁ rmly established (0·87 [0·69–1·09]). For these 
patients, prognostic models that can deﬁ ne the risk of 
developing metastatic disease, symptoms, and death 
from prostate cancer, and, for all cohorts, biomarkers 
that predict which tumours are likely to be sensitive to 
docetaxel, are needed to better inform management for 
the individual patient. Participation in protocols designed 
to address these questions is strongly encouraged.
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In 1995, when I entered the specialty of cardiac gene 
therapy, the principal limitation was the inability to 
reliably transfer genes to the cardiac ventricles. Soon 
after that time, a series of angiogenesis gene therapy 
clinical trials did not show eﬃ  cacy in randomised 
testing.1,2 Investigation of the delivery methods used 
in those studies veriﬁ ed that insuﬃ  cient gene transfer 
was a signiﬁ cant factor.3 In 2016, with the publication 
of Barry Greenberg and colleagues’ study,4 CUPID 2, we 
see that a principal limitation to cardiac gene therapy 
continues to be the inability to reliably transfer genes to 
the cardiac ventricles. In their randomised, multinational, 
double-blind, placebo-controlled, phase 2b trial, 
Greenberg and colleagues compared 121 patients 
with heart failure and reduced ejection fraction who 
received an intracoronary infusion of adeno-associated 
virus 1 (AAV1) encoding the sarcoplasmic/endoplasmic 
reticulum Ca²+-ATPase gene with 122 patients who 
received placebo. In a detailed analysis of time to 
recurrent heart failure events (primary endpoint), time 
Cardiac gene therapy: a call for basic methods development
Overall, the STAMPEDE results5 mandate a discussion of 
the proven beneﬁ t of early chemotherapy in combination 
with standard of care hormone therapy for men with 
metastatic disease at diagnosis, or who develop metastatic 
disease after local therapy with consideration to patient 
factors that might aﬀ ect tolerance and safety. Longer 
follow-up, as noted by the authors, is required before the 
beneﬁ t-to-risk ratio is deﬁ nitively established in earlier 
disease states. Needed now is a biological understanding 
of which tumours will be sensitive to docetaxel, which 
will not, and which might be more responsive to a next-
generation agent directed to the androgen receptor or 
androgen receptor signalling, or another class of drug. 
Doing so will spare patients potentially ineﬀ ective 
treatment. Equally important is the drug assessment 
paradigm established by STAMPEDE that enables new 
systemic and combined modality approaches to be 
assessed at a more rapid pace than could have been 
achieved with more traditional research designs.12 The 
trial has already, and will continue to provide, a treasure 
trove of data that directly aﬀ ects the management and 
outcomes for men with diﬀ erent states of prostate cancer.
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